RT Journal Article
T1 Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis.
A1 García-Fortes, María
A1 Hernández-Boluda, Juan C
A1 Álvarez-Larrán, Alberto
A1 Raya, José M
A1 Angona, Anna
A1 Estrada, Natalia
A1 Fox, Laura
A1 Cuevas, Beatriz
A1 García-Hernández, María C
A1 Gómez-Casares, María Teresa
A1 Ferrer-Marín, Francisca
A1 Saavedra, Silvana
A1 Cervantes, Francisco
A1 García-Delgado, Regina
A1 On Behalf Of The Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin, 
K1 comorbidities
K1 myelofibrosis
K1 prognosis
K1 survival
AB The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p
SN 2072-6694
YR 2022
FD 2022-05-09
LK http://hdl.handle.net/10668/20891
UL http://hdl.handle.net/10668/20891
LA en
DS RISalud
RD Apr 6, 2025